4//SEC Filing
Dunlop A. Sinclair 4
Accession 0000950170-24-107411
CIK 0001492422other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 5:21 PM ET
Size
8.3 KB
Accession
0000950170-24-107411
Insider Transaction Report
Form 4
Dunlop A. Sinclair
Director
Transactions
- Sale
Common Stock
2024-09-16$36.79/sh−7,524$276,808→ 100,000 total(indirect: Indirect Owner (Epidarex)) - Sale
Common Stock
2024-09-16$36.09/sh−29,476$1,063,789→ 107,524 total(indirect: Indirect Owner (Epidarex))
Holdings
- 147,526
Common Stock
Footnotes (5)
- [F1]These sales were effected pursuant to a non-Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on March 2, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $35.52 - $36.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected in footnotes (2) and (3) of this Form 4.
- [F3]This transaction was executed in multiple trades at prices ranging from $36.55 - $37.21. The price reported above reflects the weighted average sale price.
- [F4]The securities are held by Epidarex Capital I, LP ("Epidarex") and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- [F5]Includes 6,885 shares of the issuer's common stock issuable under unvested restricted stock units. Each unvested restricted stock unit represents the right to receive one share of the issuer's common stock upon vesting.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001721108
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 5:21 PM ET
- Size
- 8.3 KB